期刊文献+

可溶性T细胞免疫球蛋白和黏蛋白结构域3(sTIM3)的生物学功能及与肿瘤免疫治疗的研究进展

Research progress on the biological functions and tumor immunotherapy of soluble T-cell immunoglobulin and mucin domain 3(sTIM3)
下载PDF
导出
摘要 T细胞免疫球蛋白和黏蛋白结构域3(TIM3)是在多种免疫细胞中表达的一类免疫检查点蛋白,有膜型TIM3(mTIM3)和可溶性TIM3(sTIM3)两种形式。mTIM3和sTIM3可以结合同样的配体,但相较于mTIM3,对sTIM3的功能和作用机制了解尚少。临床上发现包括肿瘤在内的多种疾病患者的血浆sTIM3水平发生异常,目前的研究主要集中在将sTIM3作为生物标志物在肿瘤诊断和治疗监测中的潜力,而将其作为免疫治疗的靶点的研究开展较少。本文主要总结了sTIM3的产生、生物学功能及在肿瘤免疫治疗中的相关研究进展。 T-cell immunoglobulin and mucin domain 3(TIM3)is an immune checkpoint protein expressed on various types of immune cells in two forms,namely membrane TIM3(mTIM3)and soluble TIM3(sTIM3).mTIM3 and sTIM3 share the same ligands,but less is known about functions and mechanisms of sTIM3 compared to those of mTlM3.Abnormal levels of plasma sTIM3 have been observed in patients with many diseases including cancer.Current research mainly focuses on the potential of sTIM3 as a biomarker for the diagnosis and treatment of cancer.However,there are limited investigations on sTIM3 as a target for immunotherapy.This paper provides a literature review on the recent research progress of the production and biological functions of sTIM3 and its clinical significance in cancer immunotherapy.
作者 李智慧 吴凌燕 曹江 LI Zhihui;WU Lingyan;CAO Jiang(Clinical Research Center,Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China)
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2024年第8期737-742,共6页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金(81172516)。
关键词 免疫检查点 可溶性T细胞免疫球蛋白和黏蛋白结构域3(sTIM3) 肿瘤 免疫治疗 综述 immune checkpoint soluble T-cell immunoglobulin and mucin domain 3(sTIM3) tumor immune immunotherapy review
  • 相关文献

参考文献1

二级参考文献12

  • 1Fontenot JD, Gavin MA, Rudensky AY. Foxp3 program the development and function of CD4^+ CD25^+ regulatory T cells[ J]. Nat Immunol, 2003,4:330-338.
  • 2Birebent B, Lorho R, Lechartier H, et al. Suppressive properties of human CD4^+ CD25^+ regulatory T cells are dependent on CTLA-4 expression [J]. Eur J Immunol, 2004,34:1 - 12.
  • 3Staveley-O' Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy : An early event in the course of tumor progression[ J]. PNAS, 1998, 95 : 1178 - 1183.
  • 4Beck C, Schreiber H, Rowley D. Role of TGF-β in immune-evasion of Cancer[J]. Mico Res & Tech, 2001, 52:387-395.
  • 5Rich J, Borton A, Wang X. Transforming growth factor-β signaling in cancer[J]. Mico Res & Tech, 2001, 52:363-373.
  • 6Oaks MK, Hallett KM, Penwell RT, et al. A native soluble form of CTLA-4[J]. Cell Immunol, 2004, 201:144 - 153.
  • 7Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease [J].J Immunol , 2000,164:5015-5018.
  • 8Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 response and induction of peripheral tolerance[ J]. Nat Immunol, 2003, 4:1102 - 1110.
  • 9Sanchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto-and alloimmune responses and promotes immuno-logical tolerance[ J]. Nat Immunol,2003,4:1093 - 1111.
  • 10Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulate macrophage activation and severity of an auto-immune disease[J]. Nature, 2002, 415:536 - 541.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部